Delivery Order SPE2DB24D1007-SPE2DB25FB5TQ
- Not listed
- The Defense Logistics Agency awarded a $8,118.08 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ibrance 125 mg capsules (21-count packages). The contract, with a completion date of September 30, 2025, represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count package) on August 1, 2025, with an ultimate completion date of August 22, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count) on August 19, 2025, with completion targeted for September 10, 2025. The contract utilizes firm fixed pricing and was competitively awarded without a set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location....
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count) on June 18, 2025, with completion targeted for July 11, 2025. This firm fixed price contract, which carries no set-aside designation, is being fulfilled by AmerisourceBergen's Corporate Office division from its headquarters location in Conshohocken, Pennsylvania. The delivery order represents a competitive award under the company's...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ibrance 125 mg capsules (21-count units). The award is a firm fixed price contract with an ultimate completion date of October 2, 2025, and was competitively awarded with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Ibrance 125 mg capsules (21-count packages) under a firm fixed-price contract valued at $8,118.08, with completion scheduled for August 22, 2025. This non-set-aside, competitively awarded delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical vendor within the DLA's medical supply chain. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Ibrance 100 mg capsules (21-count packages) with a ceiling value of $8,122.48. This firm fixed-price delivery order, which is expected to be completed by June 24, 2025, carries no set-aside designation and represents a competitively awarded contract. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order valued at $24,367.44 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg capsules (21-count package) on August 27, 2025, with an ultimate completion date of September 18, 2025. This competitive award uses firm fixed pricing and carries no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in that...
- The Defense Logistics Agency awarded a delivery order valued at $8,122.48 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg capsules (21-count units) on September 18, 2025, with completion scheduled for October 9, 2025. This competitively awarded, firm fixed-price contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ibrance 125 mg capsules (21-count packaging). This is a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. The order is scheduled for completion by October 9, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB24D1007Indefinite Delivery Contract
- SPE2DB24D1007-SPE2DB25FB5TQDelivery Order
The Defense Logistics Agency awarded a $8,118.08 delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Ibrance 125 mg capsules (21-count packages). This firm fixed-price, competitively awarded contract is scheduled for completion by October 20, 2025, and represents performance at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award carries no set-aside designation and is issued as a child order under AmerisourceBergen's larger contract vehicle with DLA. This delivery order is executed under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime vendor agreement enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical supplies to support military and federal healthcare programs globally. The Ibrance pharmaceutical delivery aligns with AmerisourceBergen's established role as a critical distributor of specialty medications and brand-name drugs across multiple therapeutic domains for Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 9/26/25 |